Clinical trial
Phase Ⅱ Study on Ceftazidime Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection
NCT01601093 is registered in ClinicalTrials.gov with Xiangbei Welman Pharmaceutical Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase Ⅱ Study on Ceftazidime Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection
- Lead sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
- Phase
- Phase 2
- Overall status
- Suspended
- Start date
- November 30, 2011
- Completion date
- December 15, 2022
- Enrollment
- 288 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.